[An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders].

Objective: To explore the dynamics of hemostasis in patients with acute coronary syndrome (ACS) in the combination with anxiety and depressive disorders (ADD) during therapy with valdoxan (agomelatine).

Material And Methods: We examined 196 male and female patients (mean age 64.2 ± 0.

[Valproic acid pharmacogenetics in an individual approach to treatment of women of childbearing age with epilepsy].

A clinical case of the development of undesirable pharmacological phenomena in a woman of childbearing age with epilepsy is described. The development of undesirable pharmacological phenomena at reception of average therapeutic doses of valproic acid has been caused by the primary (idiopathic) and secondary (valproate-induced) infringement of a folic cycle against a combination of CYP2C9*3 gene polymorphism and a mutation in the MTHFR gene.